The high surgery cost and severe shortage of qualified doctors hospitals are two main bottlenecks for China TAVR market. Entering global markets is the only way to break ceiling and get high valuation
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.